Literature DB >> 29091885

Lipid rafts disruption induces apoptosis by attenuating expression of LRP6 and survivin in triple negative breast cancer.

Anil Kumar Badana1, Madhuri Chintala2, Murali Mohan Gavara1, Shailender Naik1, Seema Kumari1, Vijaya Rachel Kappala3, Bhaskar Reddy Iska3, Rama Rao Malla4.   

Abstract

Triple negative breast cancer is a clinically challenging subtype due to lack of biomarker for rational targeted therapy. Lipid rafts are cholesterol enriched rigid platforms, which colocalize signalling molecules of cancer progression. This study explores the effect of lipid rafts disruption by cholesterol depleting agent, MβCD on induction of apoptosis and expression of WNT receptor LRP6, survivin and common apoptotic markers in TNBC cell lines. The in vitro effect of lipid rafts disruption on viability, single cell reproductive ability, proliferation and migration were evaluated by MTT, clonogenic, BrdU incorporation and wound scratch assays, respectively. The morphological changes were assessed by tryphan blue, Wright and Giemsa staining; nuclear changes by Hoechst staining. The induction of apoptosis was evaluated by AO/EtBr staining, DNA damage and DNA fragmentation assays. Expression of Caveolin-1, LRP6, β-Catenin, Survivin, Bcl2, BAX, Caspase-3, Ki67 and c-myc were analyzed by PCR and Western blotting techniques. The lipid raft disruption resulted in reduction of the proliferation of MDA-MB 231 and MDA-MB 468 cells by 56.3 and 42.0%; survival fraction by 54.7 and 59.4%; migration by 44.3 and 48.4%, respectively. It also induced apoptosis by causing cell shrinkage, membrane blebbing, nuclear condensation, chromatin cleavage, oligonucleotide fragmentation with an apoptotic index of 59.1 and 46.6% in MDA-MB 231 and 468 cells, respectively. Further, it downregulated the expression of caveolin-1, LRP6, β-catenin, survivin, Bcl2, ki67, c-myc and upregulated BAX, caspase-3. The cholesterol supplementation enhanced the clonogenic potential and upregulated the expression of caveolin-1 and LRP6. The results underline a potential effect of lipid rafts disruption on induction of apoptosis in TNBC cells.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  LRP6; Lipid rafts; Methyl β cyclodextrin; Triple negative breast cancer

Mesh:

Substances:

Year:  2017        PMID: 29091885     DOI: 10.1016/j.biopha.2017.10.045

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

Review 1.  Lipidomic and Membrane Mechanical Signatures in Triple-Negative Breast Cancer: Scope for Membrane-Based Theranostics.

Authors:  Ruchika Dadhich; Shobhna Kapoor
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

2.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.

Authors:  Elena Alexandrova; Giorgio Giurato; Pasquale Saggese; Giovanni Pecoraro; Jessica Lamberti; Maria Ravo; Francesca Rizzo; Domenico Rocco; Roberta Tarallo; Tuula A Nyman; Francesca Collina; Monica Cantile; Maurizio Di Bonito; Gerardo Botti; Giovanni Nassa; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2019-12-02       Impact factor: 5.911

4.  Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.

Authors:  Arnaud Machelart; Giuseppina Salzano; Xue Li; Aurore Demars; Anne-Sophie Debrie; Mario Menendez-Miranda; Elisabetta Pancani; Samuel Jouny; Eik Hoffmann; Nathalie Deboosere; Imène Belhaouane; Carine Rouanet; Sophie Simar; Smaïl Talahari; Valerie Giannini; Baptiste Villemagne; Marion Flipo; Roland Brosch; Fabrice Nesslany; Benoit Deprez; Eric Muraille; Camille Locht; Alain R Baulard; Nicolas Willand; Laleh Majlessi; Ruxandra Gref; Priscille Brodin
Journal:  ACS Nano       Date:  2019-03-08       Impact factor: 15.881

Review 5.  A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers.

Authors:  Jennifer Raisch; Anthony Côté-Biron; Nathalie Rivard
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

Review 6.  Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment.

Authors:  Adele Chimento; Ivan Casaburi; Paola Avena; Francesca Trotta; Arianna De Luca; Vittoria Rago; Vincenzo Pezzi; Rosa Sirianni
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-21       Impact factor: 5.555

7.  Simvastatin Attenuates H2O2-Induced Endothelial Cell Dysfunction by Reducing Endoplasmic Reticulum Stress.

Authors:  Zhiqiang He; Xuanhong He; Menghan Liu; Lingyue Hua; Tian Wang; Qian Liu; Lai Chen; Nianlong Yan
Journal:  Molecules       Date:  2019-05-08       Impact factor: 4.411

8.  Simvastatin promotes endothelial dysfunction by activating the Wnt/β‑catenin pathway under oxidative stress.

Authors:  Zhiqiang He; Xinyue Du; Yifan Wu; Lingyue Hua; Linxi Wan; Nianlong Yan
Journal:  Int J Mol Med       Date:  2019-08-09       Impact factor: 4.101

9.  Lactate dehydrogenase B regulates macrophage metabolism in the tumor microenvironment.

Authors:  Ann-Christin Frank; Rebecca Raue; Dominik C Fuhrmann; Evelyn Sirait-Fischer; Carsten Reuse; Andreas Weigert; Dieter Lütjohann; Karsten Hiller; Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Theranostics       Date:  2021-06-04       Impact factor: 11.556

10.  Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.

Authors:  Huan-Dan Suo; Zuo Tao; Lei Zhang; Zi-Ning Jin; Xiao-Ying Li; Wei Ma; Zhen Wang; Yue Qiu; Feng Jin; Bo Chen; Yu Cao
Journal:  Biomed Res Int       Date:  2020-07-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.